Quick Answer
Kymera Therapeutics, Inc. reported Total Assets of $1.74 billion for the year ending 2025.
- Kymera Therapeutics, Inc. showed an increase of +78.2% in Total Assets from 2024 to 2025.
- This data is from Kymera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $507.36 million | Q1 2021: $464.55 million | Q2 2021: $434.39 million | Q3 2021: $642.45 million | Q1 2022: $563.06 million | Q2 2022: $523.42 million | Q3 2022: $638.47 million | Q1 2023: $613.91 million | Q2 2023: $581.95 million | Q3 2023: $552.38 million | Q1 2024: $868.25 million | Q2 2024: $826.02 million | Q3 2024: $1.03 billion | Q1 2025: $918.31 million | Q2 2025: $1.13 billion | Q3 2025: $1.10 billion.
- Over the full 7 years of available data (2019 to 2025), Kymera Therapeutics, Inc.'s Total Assets has grown by 1,393.4%.
- Historical annual values: Fiscal year 2025: $1.74 billion | Fiscal year 2024: $978.04 million | Fiscal year 2023: $575.76 million | Fiscal year 2022: $603.13 million | Fiscal year 2021: $605.91 million | Fiscal year 2020: $487.18 million | Fiscal year 2019: $116.70 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: